Top Markets
Coin of the day
Psyence Biomedical Ltd. Psyence Biomedical Ltd.

Psyence Biomedical Ltd.

PBM
株式のランク #40932
Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines... Psyence Biomedical Ltd. is dedicated to advancing psychedelic medicines formulated from botanical psilocybin. The firm is actively exploring natural psilocybin as a potential therapy for adjustment disorder experienced by patients with an incurable cancer diagnosis undergoing palliative care. Its leading investigational drug, PEX010, a capsule made with naturally sourced psilocybin, is currently in a Phase IIb clinical study. This product is being developed to treat anxiety, depression, and associated conditions such as post-traumatic stress disorder (PTSD), stress, grief, and adjustment disorder, especially in a palliative care context. Psyence Biomedical has partnered with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010, utilizing psilocybin-assisted psychotherapy for adjustment disorder arising from incurable cancer. Additionally, the company holds a strategic alliance with PsyLabs for the manufacturing of Ibogaine. Headquartered in Toronto, Canada, Psyence Biomedical Ltd. functions as a subsidiary of Psyence Group Inc.
株価
$3.20
最終同期: 2026-07-31
時価総額
$60.86K
変化(1日)
-4.76%
変化(1年)
-83.44%
CA
取引 Psyence Biomedical Ltd. (PBM)

カテゴリー

Psyence Biomedical Ltd.(PBM)の配当利回りの履歴
Psyence Biomedical Ltd.(銘柄コード: PBM)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Psyence Biomedical Ltd.(PBM)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)